BioSpace News Archive

TerrAscend Corp. (CSE:TER) (OTCQX: TRSSF) (“TerrAscend” or the “Company”) today announced that it has officially opened its seventh retail dispensary location

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Wajda v. Patel, et al. , Case: 2019-0122-JTL, a putative shareholder derivative action, was dismissed by Vice Chancellor Laster of the Chancery Court of Delaware . The derivative action was fi

Lemonaid Health, a convenient, affordable, on-demand platform for accessing healthcare online, has raised a $33 million Series B round of funding, bringing total financing to $55 million.

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced strategic changes to restructure its workforce, as it also reached another major milestone in its story with the official opening of a 91,000-square-foot, state-of-the-art factory and expanded service complex in Texas.

- Diagnostic Kit Authorized for Use on Widely Installed RT-PCR Device and High-Throughput RNA Extraction Robotics; Company Ramps Kit Production in Response - STONY BROOK, N.Y.--( BUSINESS WIRE )-- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announc

Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) continued, and the company affirmed second half of 2021 as target for completion of enrollment A post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) produced new efficacy data showing statistically significa

- On May 8, 2020, AbbVie Completed its Acquisition of Allergan, Significantly Expanding and Diversifying AbbVie’s Revenue Base with New Therapeutic Areas, Enhancing Long-Term Growth Potential, and Enabling Investment in Innovation for each of its Therapeutic Categories - Reports Second-Quarter Diluted Loss Per Share of $0.46 on a GAAP Basis; Adjusted Diluted EPS of $2.34 - Second-Quarter Net Revenues Were $10.425 Billion, an Increase of 26.3 Percent on a Reported Basis, Inclu

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced that Aoife Brennan, M.B. Ch.B., Synlogic’s president and chief executive officer, and other members of the executive team will present at the following virtual banking conferences:.

Xeris Pharmaceuticals, Inc. announced that on July 29, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares of its common stock to 4 new employees under Xeris’ Inducement Equity Plan.

Arcturus Therapeutics Holdings Inc. announced the closing on July 31, 2020 of its previously announced underwritten public offering of 3,753,773 shares of its common stock at a public offering price of $53.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions.